Reducing Risks and Optimizing Use of Biologic Therapy in Patients with Rheumatoid Arthritis

Managing a Non-Responder to Methotrexate
0.75 ANCC Contact Hours 0.75 AMA PRA Category 1 Credit(s)™
Launch Date:
December 18, 2012
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Philip J. Mease, MD

Philip J. Mease, MD
Director of Rheumatology Research, Swedish Medical Center 
Clinical Professor, University of Washington School of Medicine 
Seattle, WA

Philip J. Mease, MD, is a Clinical Professor at the University of Washington School of Medicine in Seattle and Chief of Rheumatology Clinical Research at the Swedish Hospital Medical Center. Dr. Mease is in clinical practice with Seattle Rheumatology Associates. He conducts clinical trials of emerging therapies for a number of rheumatic disease conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, lupus, osteoarthritis, fibromyalgia and osteoporosis.

He has authored numerous articles and book chapters and is on review boards for Arthritis & Rheumatism, Journal of Rheumatology, and Annals of the Rheumatic Diseases. Awards he has received include the Medical Communicator Award of the American College of Rheumatology. An advisor and educator on the study and therapy of rheumatic diseases, Dr. Mease is on the medical advisory boards of pharmaceutical and biotechnology companies, the Lupus Foundation, the Psoriasis Foundation, and the Northwest Arthritis & Osteoporosis Institute. He is a founding organizer of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), an international consortium of rheumatology and dermatology investigators and representatives of patient service leagues, the biopharmaceutical industry and regulatory agencies.

He is also chair or co-chair of three working groups of OMERACT (Outcome Measures in Rheumatology): psoriatic arthritis, fibromyalgia and single joint assessment. Dr. Mease earned his MD from Stanford University Medical School. He completed his residency in internal medicine at the University of Washington School of Medicine, where he was subsequently chief resident and fellow in rheumatology.

Jacqueline Fritz, RN, MSN, CNS

Jacqueline Fritz, RN, MSN, CNS
Medical Advancement Center
Critical Care and Rheumatology Specialist
Cypress, CA

Jacqueline Fritz, RN, MSN, CNS, is owner and Coordinator of Education at the Medical Advancement Center in Cypress, CA, where she teaches RN/BSN programs at various facilities. She is also a Critical Care Clinical Nurse Consultant to many acute care facilities in the California area, such as Cigna, Arcadia Methodist, and Doctor's Hospital of Lakewood. She is also an ACLS affiliate and West Coast Regional Director responsible for training and supervising ACLS courses in Los Angeles and Orange County.

Yusuf Yazici, MD

Yusuf Yazici, MD
Assistant Professor of Medicine
New York University
New York, NY

Yusuf Yazici, MD, is an Assistant Professor of Medicine at the New York University School of Medicine. Dr. Yazici is also the Director of the Seligman Center for Advanced Therapeutics at the NYU Hospital for Joint Diseases and Director of the Behcet's Syndrome Evaluation, Treatment and Research Center at NYU Hospital for Joint Diseases.

Dr. Yazici earned his medical degree from Cerrahpasa Medical Faculty of Istanbul University in Istanbul, Turkey. He completed his internship and residency at Creighton University in Nebraska and his fellowship in rheumatology at the Hospital for Special Surgery of Weill Medical College of Cornell University.

His areas of interest are rheumatoid arthritis, early arthritis; patient reported outcomes, database and registry management and monitoring of arthritis patients in regard to clinical response and adverse events related to treatment and Behcet's syndrome. He has published over 100 articles and presented at various national and international meetings over 100 times.
1. Implement evidence-based guidelines into practice as warranted for the treatment of specific subsets of patients with rheumatoid arthritis (RA)
2. Identify situations when the use of biologic monotherapy may be appropriate in patients with RA, based upon recently published evidence
3. Assess the clinical applicability of recent published and presented comparative effectiveness data regarding biologic therapies in RA